Overview and definition
Gigantism (pituitary gigantism) is a systemic endocrine disorder caused by chronic oversecretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) from a pituitary somatotrope adenoma—or, less often, somatotroph hyperplasia—that develops before fusion of the epiphyses, producing excessive linear growth and tall stature.[1] The lesion is not a focal jaw entity; it is a pituitary (sellar) tumor whose craniofacial and oro-dental manifestations overlap those of acromegaly and frequently bring the patient to dental attention.[2][3] GH excess acting on an actively growing skeleton drives disproportionate mandibular overgrowth, interdental spacing, and coarsened facies through accelerated condylar growth and periosteal apposition.[2] A genetic basis is identifiable in roughly half of patients, which is central to counseling and prognosis.[1][4] Management is multidisciplinary: transsphenoidal surgery is first-line, with adjuvant medical therapy and radiotherapy frequently required because these tumors are often large and invasive.[4][5]
Terminology and classification
GH excess occurring before epiphyseal fusion is termed pituitary gigantism; the same hormonal process after fusion produces acromegaly, and the two represent a continuum often labeled the acromegaly–gigantism spectrum.[1][6] The diagnostic threshold is somewhat arbitrary, generally defined as height more than 2 standard deviations (SD) above the age-, sex-, and population-adjusted mean, or more than 2 SD above mid-parental target height, with persistently elevated growth velocity.[4][7] X-linked acrogigantism (X-LAG) denotes the very early-onset form caused by Xq26.3/GPR101 duplication. "Acrogigantism" is used when classic acromegalic acral and facial features accompany the overgrowth.[7][8]
Epidemiology
GH excess is rare in childhood and adolescence, with estimated annual incidence of 3–8 cases per million person-years and prevalence of approximately 29–37 per million in those aged 0–17 years.[4][7] Among surgically treated pediatric pituitary adenomas, 8.8–21% secrete GH, with frequency rising through adolescence.[4]
- Sex: Gigantism shows an overall male preponderance, yet within the pediatric age group more diagnoses occur in girls (around 62%).[4]
- Age of onset: X-LAG presents before age 5, usually before age 2, whereas AIP-related gigantism typically emerges during the adolescent growth spurt and predominates in males.[7]
- Genetic background: An identifiable germline or mosaic alteration is found in up to 45–50% of cases—most commonly AIP (aryl hydrocarbon receptor-interacting protein) (about 29%) and GPR101 duplication (about 10%), followed by McCune–Albright syndrome, Carney complex, and MEN1.[1][9]
Clinical presentation
The most prominent and earliest feature is accelerated growth velocity (above the 97th percentile, or more than 2 SD) with progressive tall stature.[4][7] Serial heights and photographs help date onset.[4]
- Systemic/endocrine: acral enlargement, headache, visual field defects from chiasmal compression, delayed or arrested puberty, delayed bone age, and arthralgia. Delayed puberty, from prolactin co-secretion, stalk-compression hyperprolactinemia or gonadotropin deficiency, prolongs the growth window and increases final height.[4]
- Craniofacial/oro-dental: coarsening facies, frontal bossing, mandibular prognathism, dental malocclusion, and separation of the teeth; these overlap adult acromegaly and may be the presenting complaint a dentist detects first.[4][10]
- Tempo: insidious and progressive over years, contributing to diagnostic delay.[2]
- Complications/red flags: visual loss and pituitary apoplexy (mass effect), obstructive sleep apnea, insulin resistance or diabetes, hypertension, and cardiac hypertrophy with diastolic dysfunction. New visual field loss or severe headache warrants urgent pituitary evaluation.[4]
Radiographic findings
Craniofacial findings are generalized and bilaterally symmetric, reflecting systemic hormonal drive rather than a discrete osseous lesion; recognizing the pattern on dental imaging can prompt the first referral.[2][11]
Location and distribution
- The mandible is the dominant site, with disproportionate elongation and widening from accelerated condylar growth and periosteal bone apposition.[2]
- Maxillary involvement is comparatively mild, so relative mandibular overgrowth produces a skeletal Class III pattern.[11]
Growth pattern
- Slow, progressive, disproportionate enlargement over years. In gigantism these changes are superimposed on active skeletal growth, so jaw overgrowth accompanies generalized tall stature rather than the purely appositional change seen after epiphyseal fusion.[1][2]
Periphery and shape
- Increased mandibular body length and ramus height with a widened intergonial dimension, yielding a prognathic profile on lateral cephalometric projection.[3][11]
- Overall jaw thickening and widening.[2]
Relationship to teeth and the alveolar process
- Interdental spacing and diastemata (reported in roughly 40–43% of GH-excess patients) from elongation of the alveolar and basal bone.[2][3]
- Mandibular teeth are often tipped buccally or labially by an enlarged tongue.[2]
- Resulting malocclusion includes anterior open bite, reverse overjet (anterior crossbite), and Class III relationship.[2][11]
Internal architecture and effects on teeth
- Taurodontism (elongated pulp chambers with apically displaced furcations) has been reported.[2][10]
- Overgrowth affects supporting bone rather than producing a lytic or sclerotic internal matrix.[2]
Effects on adjacent structures
- Hypertrophy and pneumatization of the paranasal sinuses—especially the frontal sinus—with thickened frontal bones and a prominent glabella (frontal bossing).[3][10]
- Enlargement of the sella turcica on lateral cephalometric images, which may be the first radiographic clue to the underlying adenoma.[11]
- Condylar enlargement and remodeling with secondary degenerative temporomandibular joint change; involvement is usually symmetric but can appear asymmetric.[10][12]
Other imaging findings
Pituitary imaging
Contrast-enhanced pituitary MRI is the key study to localize and characterize the somatotrophinoma and materially directs management. Most lesions are macroadenomas, frequently invasive toward the cavernous sinus or optic chiasm; this aggressive, large-tumor profile is especially characteristic of AIP-related disease, in which roughly 93% present as macroadenomas.[4][8] Imaging also distinguishes a discrete adenoma from diffuse somatotroph hyperplasia, the latter occurring in a minority of X-LAG and McCune–Albright cases and altering surgical strategy.[7][8]
Differential diagnosis
For the oral and maxillofacial reader, the central task is separating the diffuse, hormonally driven overgrowth of gigantism from localized or constitutional causes of jaw enlargement and tall stature; biochemical confirmation (IGF-1, GH suppression) resolves most ambiguity.
| Entity | Why it is considered | Best discriminator |
|---|---|---|
| Acromegaly (post-epiphyseal GH excess) | Identical craniofacial and oro-dental overgrowth—prognathism, diastemata, taurodontism | Onset after epiphyseal fusion yields normal stature without gigantism; shared biochemical workup confirms the same etiology[2][6] |
| Nonsyndromic mandibular prognathism (familial Class III) | Mandibular overgrowth and Class III malocclusion without systemic disease | No acral enlargement, tall stature, enlarged sella, or elevated IGF-1[13] |
| Unilateral condylar hyperplasia | Progressive mandibular enlargement with occlusal cant | Asymmetric single-condyle growth rather than symmetric generalized overgrowth; normal GH/IGF-1[12] |
| Fibrous dysplasia / McCune–Albright syndrome | Craniofacial bony expansion and asymmetry, and MAS can itself cause GH excess | Focal ground-glass lesion rather than diffuse symmetric overgrowth; café-au-lait macules and precocious puberty point to MAS[4] |
| Constitutional or syndromic tall stature (e.g., Marfan, Sotos) | Excessive height overlaps gigantism | Absence of acromegalic facies; normal IGF-1 and GH suppression on oral glucose tolerance test exclude GH excess[7][14] |
The highest-risk pitfall is attributing progressive adolescent prognathism, diastemata, and Class III malocclusion to primary orthodontic or skeletal disproportion and proceeding toward orthognathic correction without recognizing active GH excess—missing an aggressive but treatable adenoma and risking recurrent deformity if hypersecretion remains uncontrolled. When the pattern is diffuse and progressive, obtain an age-adjusted serum IGF-1 and GH suppression testing, followed by pituitary MRI, and pursue genetic testing given the patient's young age.[4][14]
Histopathology
The underlying lesion is a GH-secreting pituitary adenoma (somatotrophinoma), which may be densely or sparsely granulated, and is frequently a mixed GH- and prolactin-secreting (mammosomatotroph) tumor, particularly in AIP-related and X-LAG disease.[7][8] Tumors are characteristically large and often invasive at presentation in young patients.[7][8] A minority of cases, notably X-LAG and McCune–Albright syndrome, show somatotroph hyperplasia rather than a solitary adenoma.[7][8]
Radiologic–pathologic correlation reflects end-organ IGF-1 action: craniofacial and dental changes result from periosteal/appositional bone growth and condylar growth-center reactivation rather than from any jaw-based neoplasm, so a jaw biopsy has no diagnostic role.[2] Molecular drivers meaningfully refine classification and predict behavior—AIP and GPR101 (X-LAG) alterations define aggressive, therapy-resistant subtypes, while GNAS (McCune–Albright) and MEN1 define syndromic forms.[9][15] Diagnosis rests on biochemistry, pituitary imaging, and genetic testing rather than histology of the facial skeleton.[4][14]
Management and prognosis
Confirmation is biochemical: an elevated age- and sex-adjusted serum IGF-1 and failure of GH to suppress after an oral glucose load, followed by pituitary MRI to localize the tumor.[7][14][16] Given the high yield in young patients, genetic assessment is recommended.[4][9]
- Definitive treatment: transsphenoidal surgery by an experienced pituitary neurosurgeon is first-line, offering the best chance of remission and, even when cure is unlikely, reducing GH burden to facilitate adjuvant therapy.[4][5]
- Medical therapy: adjuvant options include first-generation somatostatin receptor ligands (octreotide, lanreotide), the GH-receptor antagonist pegvisomant, cabergoline, and pasireotide; AIP- and GPR101-related tumors are frequently resistant to first-generation somatostatin analogues, often requiring pegvisomant or combination regimens. Preoperative medical therapy may rapidly control symptoms, reduce height velocity, and aid airway management.[1][4]
- Radiotherapy: generally a third-line option for residual or refractory disease.[5][16]
- Goals and surveillance: normalize growth velocity, limit final height, suppress IGF-1 into the normal range, and achieve tumor control, with longitudinal IGF-1 and auxological monitoring.[4]
Prognosis is driven by tumor size, invasiveness, and genotype; AIP and X-LAG disease is more aggressive and therapy-resistant.[1][8] Established skeletal and dental changes—including prognathism and malocclusion—are largely irreversible, so orthognathic and dental rehabilitation may be needed after hormonal control is achieved.[5][14]